Loading...
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston, S Kilburn, L Ellis, P Dodwell, D Cameron, D Hayward, L Im, Y-H Braybrooke, J Brunt, A Cheung, K-L
Johnston, S
Kilburn, L
Ellis, P
Dodwell, D
Cameron, D
Hayward, L
Im, Y-H
Braybrooke, J
Brunt, A
Cheung, K-L
Citations
Altmetric:
Abstract
The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation.
Description
Date
2013-09
Publisher
Collections
Files
Loading...
CORE by link
Adobe PDF, 582.41 KB
Keywords
Type
Article
Citation
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. 2013, 14 (10):989-98 Lancet Oncol